C:\Program Files\Stnexp\Qu[redacted]ries\812731e.str





chain nodes :
13 14 15 16 23 24 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
4-13 6-14 9-15 15-16 15-23 15-24 16-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-13 5-6 6-14 15-16 15-23 15-24 16-27
exact bonds :
9-15
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:O,S,N

G2:Cy,Ak

G3:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS

L3 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\812731e.str

L4 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d l4
L4 HAS NO ANSWERS
L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss full
FULL SEARCH INITIATED 14:14:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9329 TO ITERATE

100.0% PROCESSED 9329 ITERATIONS 87 ANSWERS
SEARCH TIME: 00.00.01

L5 87 SEA SSS FUL L3

=> s l4 sss full
FULL SEARCH INITIATED 14:14:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9329 TO ITERATE

100.0% PROCESSED 9329 ITERATIONS 624 ANSWERS
SEARCH TIME: 00.00.01

L6 624 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 310.84 313.15

FILE 'CAPLUS' ENTERED AT 14:14:29 ON 03 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
=> s l10
L11           6 L10

=> d l11 1-6 ibib abs hitstr

L11  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:        2000:190770  CAPLUS
DOCUMENT NUMBER:         132:222555
TITLE:                   Preparation of interleukin-5 inhibiting 6-azauracil
                         derivatives
INVENTOR(S):             Freyne, Eddy Jean Edgard; Lacrampe, Jean Fernand
                         Armand; Deroose, Frederik Dirk; Venet, Marc Gaston
PATENT ASSIGNEE(S):      Janssen Pharmaceutica N.V., Belg.
SOURCE:                  Eur. Pat. Appl., 37 pp.
                         CODEN: EPXXDW
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     EP 987265          A1   20000322       EP 1998-203148   19980918
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     CA 2344390         AA   20000330       CA 1999-2344390  19990914
     WO 2000017195      A1   20000330       WO 1999-EP6776   19990914
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9960825         A1   20000410       AU 1999-60825    19990914
     AU 769133          B2   20040115
     EP 1114046         A1   20010711       EP 1999-947336   19990914
     EP 1114046         B1   20030423
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002526495      T2   20020820       JP 2000-574104   19990914
     AT 238301          E    20030515       AT 1999-947336   19990914
     US 2002010177      A1   20020124       US 2001-812731   20010319
PRIORITY APPLN. INFO.:                    EP 1998-203148   A  19980918
                                          WO 1999-EP6776   W  19990914
OTHER SOURCE(S):         MARPAT 132:222555
GI
```



I



II

AB The title compds. [I; p = 0-4; X = O, S, NR5, a direct bond; Y = O, S, NR5, SO2; R1 = alkyl, halo, polyhaloalkyl, etc.; R2 = Het1, cycloalkyl, alkyl, and if X = O, S, NR5, then R2 may also represent aminocarbonyl, aminothiocarbonyl, alkylcarbonyl, etc.; R3, R4 = H, alkyl, cycloalkyl; R3R4 = alkanediyl; R5 = H, alkyl; Het1 = (un)substituted heterocycle], useful for treating eosinophil-dependent inflammatory diseases, and marking a receptor, were prepared and formulated. E.g., a multi-step synthesis of 1,2,4-triazine-3,5(2H,4H)-dione II which showed 90.5% inhibition of IL-5 production, was given.

IT **261512-38-3P 261512-45-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of interleukin-5 inhibiting 6-azauracil derivs.)

RN 261512-38-3 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-(4-phenyl-2-thiazolyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 261512-45-2 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:64782 CAPLUS
DOCUMENT NUMBER: 130:139366
TITLE: Preparation of 6-azauracil derivatives as IL-5 biosynthesis inhibitors
INVENTOR(S): Lacrampe, Jean Fernand Armand; Freyne, Eddy Jean Edgard; Venet, Marc Gaston; Boeckx, Gustaaf Maria
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902505	A1	19990121	WO 1998-EP4191	19980707
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9889738	A1	19990208	AU 1998-89738	19980707
AU 742145	B2	20011220		
EP 1000040	A1	20000517	EP 1998-941299	19980707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
EE 200000016	A	20001016	EE 2000-20000001619980707	
NZ 502180	A	20001124	NZ 1998-502180	19980707
TW 496865	B	20020801	TW 1998-87111014	19980708
ZA 9806089	A	20000110	ZA 1998-6089	19980709
BR 9811678	A	20000919	BR 1998-11678	19980710
HR 2000000003	A1	20001231	HR 2000-3	20000105
NO 2000000063	A	20000310	NO 2000-63	20000106
US 2002072603	A1	20020613	US 2001-891888	20010626

PRIORITY APPLN. INFO.: EP 1997-202118 A 19970710
WO 1998-EP4191 W 19980707
US 2000-462320 B1 20000105
OTHER SOURCE(S): MARPAT 130:139366
GI



II

AB RZCR1(XR2)R3 [I; R= 3,5-dioxo-1,2,4-triazin-2(3H)-yl; R1 = H, halo, alkyl,

alkoxy, etc.; R2 = CONH2, (un)substituted alkyl, (hetero)aryl, etc.; R3 = (un)substituted Ph; X = bond, O, s, (alkyl)imino; Z = (un)substituted phenylene] were prepared Thus, title compound II (R4 = Cl) was etherified by Me2CHCH2OH to give II (R4 = OCH2CHMe2). Data for biol. activity of I were given.

IT **219980-11-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-azauracil derivs. as IL-5 biosynthesis inhibitors)

RN 219980-11-7 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3-chloro-4-[(4-chlorophenyl)[(2-methylpropyl)thio]methyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:182798 CAPLUS

DOCUMENT NUMBER: 118:182798

TITLE: Quantitative relationship between the structure of 2-substituted 1,2,4-triazine-3,5(2H,4H)-diones and their anticoccidial activity

AUTHOR(S): Zefirov, N. S.; Petelin, D. E.; Palyulin, V. A.; McFarland, J. W.

CORPORATE SOURCE: Moscow Univ., Russia

SOURCE: Doklady Akademii Nauk (1992), 327(4-6), 504-8 [Chem.]
CODEN: DAKNEQ; ISSN: 0869-5652

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB A system of regression equations related to mol. structures and developed from literature data on 156 compds. The prognostic value of the equations for the prediction of coccidiostatic activities was tested on 13 compds. and on diclazaril, an established anticoccidial agent. The results suggested the existence of new coccidiostats in the group of triazinedione derivs.

IT **78983-76-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(coccidiostatic activity of, structure in relation to)

RN 78983-76-3 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[4-[(4-chlorophenyl)thio]-3-ethyl-5-methylphenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:439816 CAPLUS
DOCUMENT NUMBER: 117:39816
TITLE: Comparative molecular field analysis of anticoccidial triazines
AUTHOR(S): McFarland, James W.
CORPORATE SOURCE: Cent. Res. Div., Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (1992), 35(14), 2543-50
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Comparative mol. field anal. (CoMFA) of 2-(substituted phenyl)-1,2,4-triazine-3,5(2H,4H)-diones (triazines henceforth) resulted in an excellent correlation of their anticoccidial potencies with their phys. properties. Two items about this work are notable: (i) the biol. data are from a whole nimal infectious disease model; and (ii) for the best results CoMFA required columns of measured "lipophilicity" and "acidity" data in addition to the calculated data in the steric field and electrostatic field columns. CoMFA resulted in a quant. description of the major steric and electrostatic field effects, and gave significant new insights to factors governing potency. The model was used to predict the potencies of diverse triazines not used in making the model itself.

IT **78983-76-3**
RL: BIOL (Biological study)
(mol. field anal. of, anticoccidial activity and QSAR in relation to)
RN 78983-76-3 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[4-[(4-chlorophenyl)thio]-3-ethyl-5-methylphenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:580651 CAPLUS
DOCUMENT NUMBER: 95:180651
TITLE: Anticoccidial derivatives of 6-azauracil. 4. A 1000-fold enhancement of potency by phenyl sulfide and phenyl sulfone side chains

AUTHOR(S): Miller, Max W.; Mylari, Banavara L.; Howes, Harold L., Jr.; Figdor, Sanford K.; Lynch, Martin J.; Lynch, John E.; Gupta, Shyam K.; Chappel, Larry R.; Koch, Richard C.
CORPORATE SOURCE: Pfizer Med. Res. Lab., Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (1981), 24(11), 1337-42
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Thirty-nine 6-azauracils I (R and R1 = H, Cl, Me, etc.; X = Me or substituted phenyl; n = 0-2) were synthesized and tested for anticoccidial activity. These compds. prevented a broad spectrum of coccidial infections in chickens at a min. inhibitory concns. by weight in feed as low as 0.25 ppm, a 4000-fold increase in potency over 6-azauracil, and had shorter plasma half-lives than earlier potent analogs. Sulfides were more potent than sulfones, although they were oxidized rapidly to sulfones in vivo. I (R = R1 = Me; X = C6H4Cl-p; n = 0) [35319-70-1] controlled all the major species of poultry coccidia at low concns., but elicited toxicol. symptoms suggesting interference with nucleic acid synthesis.

IT **78983-76-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anticoccidial activity of, structure in relation to)

RN 78983-76-3 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[4-[(4-chlorophenyl)thio]-3-ethyl-5-methylphenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1980:51708 CAPLUS
DOCUMENT NUMBER: 92:51708
TITLE: Anticoccidial derivatives of 6-azauracil. 2. High potency and long plasma life of N1-phenyl structures
AUTHOR(S): Miller, Max W.; Mylari, Banavara L.; Howes, Harold L., Jr.; Lynch, John E.; Lynch, Martin J.; Koch, Richard C.

09/288,556

CORPORATE SOURCE: Pfizer Med. Res. Lab., Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (1979), 22(12), 1483-7
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 92:51708
GI



I

AB Forty-eight title compds. I (R = H, substituted Ph, or heterocyclic ring; R1 = H or Me; R2 = H or Ph) were synthesized, and their anticoccidial potency were determined in chickens. Maximum effects occurred with Ph rings substituted in both meta positions by compact electron-withdrawing lipophilic substituents; for example, 1-(3,5-dichlorophenyl)-6-azauracil [57715-70-5], had a plasma life of 160 h and a potency 250-fold greater than that of 6-azauracil. Structure activity relations are discussed.

IT **71609-46-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anticoccidial activity of)

RN 71609-46-6 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-(3-ethylphenyl)- (9CI) (CA INDEX NAME)



=>

FILE COVERS 1907 - 3 Mar 2004 VOL 140 ISS 10
FILE LAST UPDATED: 2 Mar 2004 (20040302/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L7 104 L5

=> s l6
L8 7 L6

=> d l8 1-7 ibib abs hitstr

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:115148 CAPLUS
DOCUMENT NUMBER: 134:178571
TITLE: Preparation of 6-azauracil derivatives as interleukin-5 inhibitors
INVENTOR(S): Lacrampe, Jean Fernand Armand; Freyne, Eddy Jean Edgard; Deroose, Frederik Dirk; Fortin, Jerome Michel Claude; Coesemans, Erwin
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010866	A1	20010215	WO 2000-EP7358	20000731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013014	A	20020416	BR 2000-13014	20000731
EP 1206471	A1	20020522	EP 2000-948015	20000731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506451	T2	20030218	JP 2001-515675	20000731
EE 200200057	A	20030415	EE 2002-57	20000731
BG 106367	A	20020930	BG 2002-106367	20020130
NO 2002000565	A	20020326	NO 2002-565	20020205
ZA 2002001007	A	20030505	ZA 2002-1007	20020205
US 2003114453	A1	20030619	US 2002-75876	20020214

PRIORITY APPLN. INFO.:		
EP 1999-870170	A	19990806
EP 1999-126035	A	19991227
WO 2000-EP7358	W	20000731

09/288,556

OTHER SOURCE(S): MARPAT 134:178571
GI



I



II

AB The title compds. (I) [p = 0-4; X = O, S, NR5, or a direct bond; or XR2 taken together = CN; R1 = independently C(O)ZR14, (un)substituted alkyl, halo, OH, SH, alkoxy, alkylthio, alkylcarbonyloxy, aryl, CN, NO2, hetercyclyl, R6, or NR7R8; R2 = heterocyclyl, (un)substituted cycloalkyl, alkoxy, or alkylthio, heterocyclyl(oxy), heterocyclylthio, etc.; R3 and R4 = independently H or (cyclo)alkyl; or R3 and R4 taken together form an alkenediyl; R5 = H or alkyl; R6 = (un)substituted (cyclo)alkylsulfonyl, amino(alkyl)sulfonyl, heterocyclylsulfonyl, etc.; R7 and R8 = independently H, (cyclo)alkyl, (di)hydroxyalkyl, mercaptoalkyl, aryl(alkyl), alkyloxyalkyl, alkyl(thio)carbonyl, aryl(thio)carbonyl, heterocyclyl(thio)carbonyl, C(O)ZR14, or (un)substituted aminocarbonyl, etc.; or R7 and R8 together with the N to which they are attached form a pyrrolinone, piperidinone, or hexahydroazepinone; R14 = H, alkynyl, or (un)substituted (alkyl)acyl, alkyl, alkenyl, heterocyclyl, etc.; Z = O, S, NH, CH2O, or CH2S; or ZR14 taken together = CH2CN or CH2PO3H2 and its esters] and their N-oxides, pharmaceutically acceptable salts, or stereochem. isomers were prepared as selective chemokine inhibitors. For example, 2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-α,α-dimethylbenzeneethanethioamide was coupled with Et β-bromo-γ-oxobenzenebutanoate (46.5%), cyclized to form the thiazoleacetic acid (79%), and esterified with 3-bromodihydro-2(3H)-furanone to give II. As selective interleukin 5 (IL-5) and monocyte chemotactic protein-1 and -3 (MCP-1 and MCP-3) inhibitors, I are useful for treating eosinophil-dependent inflammatory diseases, especially bronchial asthma (no data). Processes using I for marking receptors and imaging organs via radiolabeling are also claimed.

IT **261511-42-6P 261511-51-7P 261512-22-5P**
325968-64-7P 325968-65-8P 325968-66-9P
325968-67-0P 325968-70-5P 325968-71-6P
325968-72-7P 325968-81-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of IL-5 inhibiting thiazolylalkylphenyl-6-azauracil derivs. by coupling of 4-dioxotriazinyl-α,α-dimethylbenzeneethanethioamides with α-oxoalkyl halides, cyclization, and addition of functionally substituted groups)

RN 261511-42-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 261511-51-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 261512-22-5 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-methyl-1-[5-(2-methylphenyl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 325968-64-7 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 325968-65-8 CAPLUS
CN 5-Thiazolecarboxylic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 325968-66-9 CAPLUS
CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-(2-thienyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 325968-67-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 325968-70-5 CAPLUS
CN Benzeneacetonitrile, 2-[3-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



RN 325968-71-6 CAPLUS
CN Benzeneacetic acid, 2-[3-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



RN 325968-72-7 CAPLUS
CN Benzeneacetyl chloride, α,α-dichloro-2-[3-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:779748 CAPLUS
DOCUMENT NUMBER: 134:80637
TITLE: Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis
AUTHOR(S): Van Wauwe, Jean; Aerts, Frans; Cools, Marina; Deroose, Frederik; Freyne, Eddy; Goossens, Jan; Hermans, Bart; Lacrampe, Jean; Van Genechten, Heidi; Van Gerven, Frans; Van Nyen, Greta
CORPORATE SOURCE: Janssen Research Foundation, Beerse, Belg.
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2000), 295(2), 655-661
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Interleukin (IL)-5 regulates the growth, differentiation, and activation of eosinophils. When activated, eosinophils release an array of proinflammatory and cytotoxic products and act as prominent effector cells in the process of allergic inflammation. Depriving eosinophils of IL-5 may therefore represent a viable approach to treat allergic disorders. This study describes the identification of R146225, a novel six-substituted azauracil derivative, as a potent, orally active inhibitor of IL-5 biosynthesis, capable of reducing pulmonary eosinophilia in mice. In vitro, R146225 inhibited IL-5 protein formation by activated human whole blood (IC50 = 34 nM), human peripheral blood mononuclear cells (IC50 = 24 nM), and murine spleen cells (IC50 = 6 nM). In contrast, the compound enhanced generation of interferon-γ and had little or no inhibitory effect on the production of IL-2 and IL-4. Reverse transcription-polymerase chain reaction anal. of stimulated whole blood cells indicated R146225's ability to down-regulate IL-5 mRNA expression. In vivo p.o. administration of R146225 (2.5 mg/kg) to mice before an i.v. anti-CD3 antibody challenge reduced IL-5 but enhanced interferon-γ serum levels, without affecting IL-2 and IL-4 production Analogous to the in vitro results, R146225 suppressed splenic IL-5 mRNA expression, while message levels of the other cytokines remained unchanged. Moreover, p.o. dosing of R146225 (0.6-2.5 mg/kg) dose dependently reduced the pulmonary accumulation of eosinophils induced in mice by an intranasal instillation of Cryptococcus neoformans. Based on these data, R146225 may be useful in the therapy of eosinophil-driven allergic conditions.

IT **219979-42-7**, R 146225
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of R146225 on interleukin-5 biosynthesis and pulmonary eosinophilia)
RN 219979-42-7 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[(4-chlorophenyl)(2-pyrimidinylthio)methyl]phenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:441780 CAPLUS
DOCUMENT NUMBER: 133:74040
TITLE: Preparation of IL-5 inhibiting 6-azauracil derivatives
INVENTOR(S): Freyne, Eddy Jean Edgard; Deroose, Frederik Dirk; Lacrampe, Jean Fernand Armand; Embrechts, Werner Constant Johan; Fortin, Jerome Michel Claude
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037451	A1	20000629	WO 1999-EP10169	19991216
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9916366	A	20010918	BR 1999-16366	19991216
EP 1140873	A1	20011010	EP 1999-965509	19991216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533331	T2	20021008	JP 2000-589523	19991216
EE 200100320	A	20021015	EE 2001-320	19991216
BG 105602	A	20020131	BG 2001-105602	20010614
NO 2001002987	A	20010817	NO 2001-2987	20010615
ZA 2001004942	A	20020618	ZA 2001-4942	20010615
HR 2001000455	A1	20020630	HR 2001-455	20010615

PRIORITY APPLN. INFO.: EP 1998-204336 A 19981218
WO 1999-EP10169 W 19991216
OTHER SOURCE(S): MARPAT 133:74040
GI



I



II

AB The title compds. (I) [wherein p = 0-4; q = 0-5; X = O, S, NH, N(alkyl), or a bond; or XR2 = CN; R1 = H, OH, halo, (mono or dialkyl)NH2, (cyclo)alkyl, alkoxy, aryl(alkyl), etc.; R2 = aryl, heterocyclyl, or (un)substituted (cyclo)alkyl; R3 = H or alkyl; R4 and R5 = independently C(O)ZR14, (halo)alkyl, halo, OH, SH, alkoxy, alkylthio, acyloxy, aryl, CN, NO2, heterocyclyl, (un)substituted amino or alkyl; Z = O, S, NH, CH2O, or CH2S; R14 = H, (un)substituted acyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, or Ph] and their N-oxides, pharmaceutically acceptable salts, quaternary amines, or stereochem. isomers were prepared as selective chemokine inhibitors. For example, II was formed in a 3-step sequence involving the (1) coupling of 2-[3,5-dichloro-4-[(4-chlorophenyl)hydroxymethyl]phenyl]-1,2,4-triazine-3,5(2H,4H)dione with 1,2-dihydro-2-thioxo-3-pyridinecarboxylic acid (91%), (2) thiolation of the acid (100%), and (3) esterification with 3-bromodihydro-2(3H)-furanone (42%). As selective interleukin 5 (IL-5) and monocyte chemotactic protein-1 and -3 (MCP-1 and MCP-3) inhibitors, I are useful for treating eosinophil-dependent inflammatory diseases, especially bronchial asthma (no data). Processes using I for marking receptors and imaging organs via radiolabelling are also claimed.

IT **278793-37-6P 278793-38-7P 278793-39-8P 278793-40-1P 278793-41-2P 278793-42-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of IL-5 inhibiting 6-azauracil derivs. by coupling hydroxymethylphenyl-6-azauracils with thioxopyridinecarboxylic acids followed by reduction or thiolation and addition of a functionally substituted group)

RN 278793-37-6 CAPLUS

CN 3-Pyridinecarbothioic acid, 2-[[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]thio]-,

S-(tetrahydro-2-oxo-3-furanyl) ester (9CI) (CA INDEX NAME)



RN 278793-38-7 CAPLUS
CN 1-Piperazineacetic acid, 4-[[2-[[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]thio]-3-pyridinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 278793-39-8 CAPLUS
CN 1-Piperidineacetic acid, 4-[[[2-[[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]thio]-3-pyridinyl]methyl]methylamino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 278793-40-1 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[6-[[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]thio]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 278793-41-2 CAPLUS
CN Glycine, N-[[2-[[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]thio]-3-pyridinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 278793-42-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]thio]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (9CI) (CA INDEX NAME)



IT **278793-43-4P 278793-44-5P 278793-45-6P**
278793-46-7P 278793-47-8P 278793-48-9P
278793-49-0P 278793-50-3P 278793-51-4P
278793-52-5P 278793-53-6P 278793-54-7P
278793-55-8P 278793-56-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of IL-5 inhibiting 6-azauracil derivs. by coupling hydroxymethylphenyl-6-azauracils with thioxopyridinecarboxylic acids followed by reduction or thiolation and addition of a functionally substituted group)

RN 278793-43-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:190770 CAPLUS
DOCUMENT NUMBER: 132:222555
TITLE: Preparation of interleukin-5 inhibiting 6-azauracil derivatives
INVENTOR(S): Freyne, Eddy Jean Edgard; Lacrampe, Jean Fernand Armand; Deroose, Frederik Dirk; Venet, Marc Gaston
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 987265	A1	20000322	EP 1998-203148	19980918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2344390	AA	20000330	CA 1999-2344390	19990914
WO 2000017195	A1	20000330	WO 1999-EP6776	19990914
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9960825	A1	20000410	AU 1999-60825	19990914
AU 769133	B2	20040115		
EP 1114046	A1	20010711	EP 1999-947336	19990914
EP 1114046	B1	20030423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526495	T2	20020820	JP 2000-574104	19990914
AT 238301	E	20030515	AT 1999-947336	19990914
US 2002010177	A1	20020124	US 2001-812731	20010319

PRIORITY APPLN. INFO.: EP 1998-203148 A 19980918
WO 1999-EP6776 W 19990914

OTHER SOURCE(S): MARPAT 132:222555
GI



I



II

AB The title compds. [I; p = 0-4; X = O, S, NR5, a direct bond; Y = O, S,

NR5, SO2; R1 = alkyl, halo, polyhaloalkyl, etc.; R2 = Het1, cycloalkyl, alkyl, and if X = O, S, NR5, then R2 may also represent aminocarbonyl, aminothiocarbonyl, alkylcarbonyl, etc.; R3, R4 = H, alkyl, cycloalkyl; R3R4 = alkanediyl; R5 = H, alkyl; Het1 = (un)substituted heterocycle], useful for treating eosinophil-dependent inflammatory diseases, and marking a receptor, were prepared and formulated. E.g., a multi-step synthesis of 1,2,4-triazine-3,5(2H,4H)-dione II which showed 90.5% inhibition of IL-5 production, was given.

IT **261511-42-6P 261511-51-7P 261511-57-3P**
261511-62-0P 261511-73-3P 261511-81-3P
261511-82-4P 261511-89-1P 261511-90-4P
261511-92-6P 261511-93-7P 261512-09-8P
261512-15-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of interleukin-5 inhibiting 6-azauracil derivs.)

RN 261511-42-6 CAPLUS
CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 261511-51-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 261511-57-3 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[4-[1-(5-benzoyl-4-phenyl-2-thiazolyl)-1-methylethyl]-3,5-dichlorophenyl]- (9CI) (CA INDEX NAME)



RN 261511-62-0 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-[5-(methoxymethyl)-4-phenyl-2-thiazolyl]-1-methylethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 261511-73-3 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[4-[1-[5-(bromomethyl)-4-phenyl-2-thiazolyl]-1-methylethyl]-3,5-dichlorophenyl]- (9CI) (CA INDEX NAME)



RN 261511-81-3 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-methyl-1-[5-(3-nitrophenyl)-4-phenyl-2-thiazolyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 261511-82-4 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[4-[1-[5-(3-aminophenyl)-4-phenyl-2-thiazolyl]-1-methylethyl]-3,5-dichlorophenyl]- (9CI) (CA INDEX NAME)



RN 261511-89-1 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-[5-(3-methoxyphenyl)-4-phenyl-2-thiazolyl]-1-methylethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 261511-90-4 CAPLUS
CN Benzoic acid, 3-[4-(2-chlorophenyl)-2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 261511-92-6 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-[5-(3-hydroxyphenyl)-4-phenyl-2-thiazolyl]-1-methylethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 261511-93-7 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[1-[4-(2-chlorophenyl)-5-[3-(hydroxymethyl)phenyl]-2-thiazolyl]-1-methylethyl]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:64782 CAPLUS
DOCUMENT NUMBER: 130:139366
TITLE: Preparation of 6-azauracil derivatives as IL-5 biosynthesis inhibitors
INVENTOR(S): Lacrampe, Jean Fernand Armand; Freyne, Eddy Jean Edgard; Venet, Marc Gaston; Boeckx, Gustaaf Maria
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902505	A1	19990121	WO 1998-EP4191	19980707
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9889738	A1	19990208	AU 1998-89738	19980707
AU 742145	B2	20011220		
EP 1000040	A1	20000517	EP 1998-941299	19980707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
EE 200000016	A	20001016	EE 2000-20000001619980707	
NZ 502180	A	20001124	NZ 1998-502180	19980707
TW 496865	B	20020801	TW 1998-87111014	19980708
ZA 9806089	A	20000110	ZA 1998-6089	19980709
BR 9811678	A	20000919	BR 1998-11678	19980710
HR 2000000003	A1	20001231	HR 2000-3	20000105
NO 2000000063	A	20000310	NO 2000-63	20000106
US 2002072603	A1	20020613	US 2001-891888	20010626

PRIORITY APPLN. INFO.: EP 1997-202118 A 19970710
WO 1998-EP4191 W 19980707
US 2000-462320 B1 20000105
OTHER SOURCE(S): MARPAT 130:139366
GI



II

AB RZCR1(XR2)R3 [I; R= 3,5-dioxo-1,2,4-triazin-2(3H)-yl; R1 = H, halo, alkyl, alkoxy, etc.; R2 = CONH2, (un)substituted alkyl, (hetero)aryl, etc.; R3 = (un)substituted Ph; X = bond, O, s, (alkyl)imino; Z = (un)substituted phenylene] were prepared Thus, title compound II (R4 = Cl) was etherified by Me2CHCH2OH to give II (R4 = OCH2CHMe2). Data for biol. activity of I were given.

IT **219976-89-3P 219976-90-6P 219976-92-8P**
219976-93-9P 219976-96-2P 219976-99-5P
219977-02-3P 219977-05-6P 219977-08-9P
219977-09-0P 219977-11-4P 219977-13-6P
219977-15-8P 219977-18-1P 219977-19-2P
219977-20-5P 219977-21-6P 219977-22-7P
219977-23-8P 219977-24-9P 219977-25-0P
219977-27-2P 219977-28-3P 219977-29-4P
219977-30-7P 219977-31-8P 219977-32-9P
219977-33-0P 219977-34-1P 219977-35-2P
219977-36-3P 219977-37-4P 219977-38-5P
219977-39-6P 219977-40-9P 219977-41-0P
219977-42-1P 219977-43-2P 219977-44-3P
219977-45-4P 219977-46-5P 219977-47-6P
219977-48-7P 219977-49-8P 219977-50-1P
219977-51-2P 219977-52-3P 219977-53-4P
219977-54-5P 219977-55-6P 219977-56-7P
219977-57-8P 219977-58-9P 219977-59-0P
219977-60-3P 219977-61-4P 219977-62-5P
219977-63-6P 219977-64-7P 219977-65-8P
219977-66-9P 219977-67-0P 219977-68-1P
219977-69-2P 219977-70-5P 219977-71-6P
219977-72-7P 219977-73-8P 219977-75-0P
219977-76-1P 219977-77-2P 219977-78-3P
219977-79-4P 219977-80-7P 219977-81-8P
219977-82-9P 219977-83-0P 219977-84-1P
219977-85-2P 219977-86-3P 219977-88-5P
219977-90-9P 219977-91-0P 219977-92-1P
219977-93-2P 219977-95-4P 219977-96-5P
219977-97-6P 219977-99-8P 219978-00-4P
219978-01-5P 219978-02-6P 219978-03-7P
219978-05-9P 219978-06-0P 219978-07-1P
219978-08-2P 219978-10-6P 219978-11-7P
219978-12-8P 219978-13-9P 219978-14-0P
219978-15-1P 219978-16-2P 219978-17-3P
219978-18-4P 219978-23-1P 219978-24-2P
219978-25-3P 219978-26-4P 219978-27-5P
219978-30-0P 219978-31-1P 219978-32-2P
219978-36-6P 219978-40-2P 219978-41-3P
219978-42-4P 219978-43-5P 219978-44-6P
219978-45-7P 219978-46-8P 219978-48-0P
219978-49-1P 219978-50-4P 219978-52-6P
219978-53-7P 219978-54-8P 219978-56-0P
219978-57-1P 219978-58-2P 219978-59-3P
219978-60-6P 219978-61-7P 219978-62-8P
219978-63-9P 219978-64-0P 219978-66-2P
219978-67-3P 219978-68-4P 219978-69-5P
219978-70-8P 219978-71-9P 219978-72-0P
219978-73-1P 219978-74-2P 219978-75-3P
219978-76-4P 219978-77-5P 219978-78-6P
219978-79-7P 219978-80-0P 219978-81-1P
219978-82-2P 219978-83-3P 219978-84-4P
219978-85-5P 219978-87-7P 219978-88-8P
219978-89-9P 219978-90-2P 219978-91-3P

219978-92-4P 219978-93-5P 219978-94-6P
219978-95-7P 219978-96-8P 219978-97-9P
219978-98-0P 219978-99-1P 219979-00-7P
219979-01-8P 219979-02-9P 219979-03-0P
219979-04-1P 219979-05-2P 219979-06-3P
219979-07-4P 219979-08-5P 219979-09-6P
219979-10-9P 219979-11-0P 219979-12-1P
219979-13-2P 219979-14-3P 219979-15-4P
219979-16-5P 219979-17-6P 219979-18-7P
219979-19-8P 219979-20-1P 219979-21-2P
219979-22-3P 219979-23-4P 219979-24-5P
219979-25-6P 219979-26-7P 219979-27-8P
219979-28-9P 219979-29-0P 219979-30-3P
219979-31-4P 219979-32-5P 219979-33-6P
219979-34-7P 219979-35-8P 219979-36-9P
219979-37-0P 219979-38-1P 219979-39-2P
219979-40-5P 219979-41-6P 219979-42-7P
219979-43-8P 219979-44-9P 219979-45-0P
219979-46-1P 219979-47-2P 219979-48-3P
219979-49-4P 219979-50-7P 219979-51-8P
219979-52-9P 219979-54-1P 219979-55-2P
219979-56-3P 219979-57-4P 219979-58-5P
219979-59-6P 219979-60-9P 219979-61-0P
219979-62-1P 219979-63-2P 219979-64-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-azauracil derivs. as IL-5 biosynthesis inhibitors)

RN 219976-89-3 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3-chloro-4-[(4-chlorophenyl)(2-methyl-4-phenyl-5-thiazolyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 219976-90-6 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[(4-chlorophenyl)[4-(2-chlorophenyl)-2-methyl-5-thiazolyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 219976-92-8 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[(4-chlorophenyl)(2-methyl-4-phenyl-5-thiazolyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 219976-93-9 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[(4-chlorophenyl)[2-(2-chlorophenyl)-4-methyl-5-thiazolyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 219976-96-2 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[(4-chlorophenyl)(4-methyl-2-phenyl-5-thiazolyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 219976-99-5 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3-chloro-4-[(4-chlorophenyl)[4-(2-chlorophenyl)-2-methyl-5-thiazolyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 219977-02-3 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3-chloro-4-[(4-chlorophenyl)(2,4-diphenyl-5-thiazolyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:204457 CAPLUS
DOCUMENT NUMBER: 128:244065
TITLE: Preparation of 1,2,4-triazine-3,5-diones as anticoccidial agents
INVENTOR(S): Miki, Hideki; Iwanaga, Koichi; Aoki, Isao; Hayashi, Toshikatsu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 831088	A1	19980325	EP 1997-115045	19970829
EP 831088	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2214256	AA	19980228	CA 1997-2214256	19970829
CN 1175577	A	19980311	CN 1997-117551	19970829
CN 1128141	B	20031119		
JP 10120662	A2	19980512	JP 1997-233448	19970829
US 5985875	A	19991116	US 1997-921047	19970829

PRIORITY APPLN. INFO.: JP 1996-230434 A 19960830
OTHER SOURCE(S): MARPAT 128:244065
GI



I

provisoed

AB The title compds. [I; A = N, CH; R1 = (un)substituted alkyl optionally bonded via heteroatom, (un)substituted acyl, alkylsulfonyl, alkylsulfinyl, (un)substituted sulfamoyl; R2 = H, (halo)alkyl optionally bonded via heteroatom; R3 = H, halo, alkyl; R4 = H, H, (un)substituted alkyl or acyl; X1 = halo, alkyl; X2 = H, F; a proviso is given] and their salts, useful as antiprotozoal agents, were prepared Thus, 2-[4-[4-(4-chlorobenzoyl)benzyl]-3,5-dichlorophenyl]-1,2,4-triazine-3,5(2H,4H)-dione (multistep preparation from 4-ClC6H4COCl and 4,3,5-(PhCH2)Cl2C6H2NO2 given) at 31.3 ppm in standard feed ration in chicks inoculated with Eimeria tenella sporulating oocysts gave relative body weight gain of 103.4% with 0 bloody droppings and the number of oocysts excreted in each g of stool "not detected", vs. 33.0%, 9.0 and 6.0 for an infected and untreated control group.

IT **205104-50-3P 205104-55-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazinedione derivs. as anticoccidial agents)

RN 205104-50-3 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[[6-(methylthio)-3-pyridinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 205104-55-8 CAPLUS
CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[[6-(methylsulfinyl)-3-pyridinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:712918 CAPLUS
DOCUMENT NUMBER: 126:8142
TITLE: Method of producing 1,2,4-triazin-3-one derivatives by cyclizing semicarbazone derivatives
INVENTOR(S): Miki, Hideki; Iwanaga, Koichi; Aoki, Isao
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

provisoed

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 737672	A2	19961016	EP 1996-105485	19960404
EP 737672	A3	19961227		
EP 737672	B1	20011004		
R: BE, CH, DE, FR, GB, LI, NL				
JP 08337576	A2	19961224	JP 1996-89294	19960411
CA 2174063	AA	19961015	CA 1996-2174063	19960412
CN 1140712	A	19970122	CN 1996-104625	19960412
CN 1062265	B	20010221		
US 5994355	A	19991130	US 1997-810499	19970228

US 6211178 B1 20010403 US 1999-335918 19990618
PRIORITY APPLN. INFO.: JP 1995-89786 A 19950414
JP 1993-258654 A 19931015
JP 1994-223761 A 19940919
US 1994-322489 B3 19941014
US 1996-602451 B2 19960216
US 1996-632580 B2 19960415
US 1996-755059 B1 19961122
US 1997-810499 A3 19970228
OTHER SOURCE(S): CASREACT 126:8142; MARPAT 126:8142
GI


I


III

AB The title compds. [I; R1 = (un)substituted hydrocarbon; X = CO, CS, an optionally substituted CH2; dashed line = optional double bond] prepared in an industrial manner conveniently and simply in high yield by cyclizing semicarbazone derivs. represented by R1N(N:CR2R3)CONHCH2CH(OR4)2 (R2, R3 = H, an optionally substituted hydrocarbon, an electron withdrawing group; R4 = an optionally substituted alkyl) (II). II are prepared by reacting hydrazone derivs. represented by R1NHN:CR2R3 with dialkoxyethyl isocyanates represented by (R4O)2CHCH2NCO. I are useful as herbicides, pesticides, parasiticides, and veterinary drugs (no data). Thus, 1-benzylidene-2-[4-(4-chlorobenzyl)-3,5-dichlorophenyl]-4-(2,2-diethoxyethyl)semicarbazide was cyclized in the presence of 35% HCl to give 90% 2-[3,5-dichloro-4-(4-chlorobenzyl)phenyl]-4,5-dihydro-1,2,4-triazine-3(2H)-one, which was oxidized by H2O2 to give 85% the title compound (III).

IT **183603-75-0P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazinone derivs. by cyclizing semicarbazone derivs.)

RN 183603-75-0 CAPLUS

CN 1,2,4-Triazine-3,5(2H,4H)-dione, 2-[3,5-dichloro-4-[(6-chloro-3-pyridinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



09/288,556

=>